Vaccination with allogeneic dendritic cells fused to carcinoma cells induces antitumor immunity in MUC1 transgenic mice
- PMID: 11683578
- DOI: 10.1006/clim.2001.5112
Vaccination with allogeneic dendritic cells fused to carcinoma cells induces antitumor immunity in MUC1 transgenic mice
Abstract
Fusions of autologous tumor cells with allogeneic dendritic cells (DC) represent an approach for the induction of antitumor immunity. In the present studies, we investigated the antitumor effects of vaccinating MUC1-transgenic (MUC1.Tg) mice with MC38/MUC1 carcinoma cells fused to allogeneic DC from BALB/c mice (allo-DC, H-2(d)) or syngeneic DC from C57BL/6 mice (syn-DC, H-2(b)). Both allo and syn fusion cells (FC/MUC1) expressed MHC class II, costimulatory molecules, and the MUC1 antigen. Allo-FC/MUC1 exhibited dual expression of MHC class I haplotypes (H-2(d)/H-2(b))and MUC1 antigen. By contrast, only H-2(b) and MUC1 antigen were expressed by syn-FC/MUC1. CTLs from MUC1.Tg mice immunized with allo- or syn-FC/MUC1 fusion cells lysed MC38/MUC1 targets. Moreover, immunization with allo- or syn-FC/MUC1 was effective in eliminating established MUC1-positive pulmonary metastases in MUC1.Tg mice. These results indicate that immunization of MUC1.Tg mice with syn- or allo-FC/MUC1 is effective in reversing immunologic unresponsiveness to MUC1 antigen and inducing immunity against MUC1-positive tumors. The findings in the present study have broader clinical implications for fusion cell vaccines.
Copyright 2001 Academic Press.
Similar articles
-
Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines.J Immunol. 1998 Nov 15;161(10):5516-24. J Immunol. 1998. PMID: 9820528
-
Induction of impaired antitumor immunity by fusion of MHC class II-deficient dendritic cells with tumor cells.J Immunol. 2005 Feb 1;174(3):1274-80. doi: 10.4049/jimmunol.174.3.1274. J Immunol. 2005. PMID: 15661883
-
Intradermal vaccination of MUC1 transgenic mice with MUC1/IL-18 plasmid DNA suppresses experimental pulmonary metastases.Vaccine. 2007 Apr 30;25(17):3338-46. doi: 10.1016/j.vaccine.2007.01.007. Epub 2007 Jan 22. Vaccine. 2007. PMID: 17292519
-
Assessment of fusion cells from patient-derived ovarian carcinoma cells and dendritic cells as a vaccine for clinical use.Gynecol Oncol. 2005 Nov;99(2):462-71. doi: 10.1016/j.ygyno.2005.07.019. Epub 2005 Aug 30. Gynecol Oncol. 2005. PMID: 16137749 Review.
-
MUC1 and breast cancer.Curr Opin Mol Ther. 1999 Feb;1(1):98-103. Curr Opin Mol Ther. 1999. PMID: 11249691 Review.
Cited by
-
Dendritic cells induce immunity and long-lasting protection against blood-stage malaria despite an in vitro parasite-induced maturation defect.Infect Immun. 2004 Sep;72(9):5331-9. doi: 10.1128/IAI.72.9.5331-5339.2004. Infect Immun. 2004. PMID: 15322030 Free PMC article.
-
Generation and functional assessment of antigen-specific T cells stimulated by fusions of dendritic cells and allogeneic breast cancer cells.Vaccine. 2007 Mar 30;25(14):2610-9. doi: 10.1016/j.vaccine.2006.12.035. Epub 2007 Jan 3. Vaccine. 2007. PMID: 17239504 Free PMC article.
-
Whole tumor antigen vaccines.Semin Immunol. 2010 Jun;22(3):132-43. doi: 10.1016/j.smim.2010.02.004. Epub 2010 Mar 30. Semin Immunol. 2010. PMID: 20356763 Free PMC article. Review.
-
Antigen-specific polyclonal cytotoxic T lymphocytes induced by fusions of dendritic cells and tumor cells.J Biomed Biotechnol. 2010;2010:752381. doi: 10.1155/2010/752381. Epub 2010 Apr 7. J Biomed Biotechnol. 2010. PMID: 20379390 Free PMC article.
-
Dendritic-Tumor Fusion Cell-Based Cancer Vaccines.Int J Mol Sci. 2016 May 26;17(6):828. doi: 10.3390/ijms17060828. Int J Mol Sci. 2016. PMID: 27240347 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous